2024 Adaptive biotechnologies stock - Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT on NasdaqGS.

 
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune .... Adaptive biotechnologies stock

The estimated net worth of Chad M. Cohen is at least $134,139.07 as of September 7th, 2021. Mr. Cohen owns 30,979 shares of Adaptive Biotechnologies stock worth more than $134,139 as of November 28th. This net worth evaluation does not reflect any other investments that Mr. Cohen may own. Learn More about Chad M. Cohen's net …Real time Adaptive Biotechnologies (ADPT) stock price quote, stock graph, news & analysis.Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued.The advantages of biotechnology include curing infectious diseases, creating more efficient fuels and increasing farming yields to feed more people. Disadvantages of biotechnology include antibiotic resistant bacteria, new allergic reaction...SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Oct 4, 2023 · Adaptive Biotechnologies Corp is down 7.85% from its previous closing price of $5.22. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $5.12 and $5.30. Currently, there are 144.40 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s P ... Piper Sandler has a $15 target price for Adaptive Biotechnologies stock. The consensus target is $12.29, and shares closed on Friday at $7.46, which was up almost 6% for the day.Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual ... SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...Adaptive Biotechnologies: Stock Isn't Cheap. Jun. 04, 2021 4:10 PM ET Adaptive Biotechnologies Corporation (ADPT) 7 Comments 3 Likes. Avisol Capital Partners. Investing Group Leader. Follow.Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...Oct 17, 2023 · The latest Adaptive Biotechnologies Corporation Registered Shs stock prices, stock quotes, news, and ADPT history to help you invest and trade smarter. THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing …Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ...Adaptive Biotechnologies Corp Follow Share $4.62 After Hours: $4.62 (0.00%) 0.00 Closed: Nov 29, 4:18:17 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to AbbVie Inc $138.50 ABBV0.0072%... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to …Nov 2, 2023 · Stock. Stock Quote & Chart ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune ... On November 9, Adaptive Biotechnologies will report earnings from Q3. Wall Street analysts predict losses per share of $0.339. Track Adaptive Biotechnologies stock price in real-time ahead here ...Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose …Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter of 2023 …Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2021 and December 31, 2020; 140,663,755 and 137,646,896 shares issued and outstanding at June 30, 2021 and …SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ...Adaptive Biotechnologies Stock Performance. NASDAQ ADPT opened at $4.33 on Tuesday. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The company has a 50-day ...Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine.Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look ...Adaptive Biotechnologies Chief Scientific Officer Harlan Robins signs the final beam during a “topping off” ceremony at the company’s future headquarters on Thursday, 23, 2020 in Seattle ...Bluebird Bio. Market Cap. $466M. Today's Change. (11.52%) $0.44. Current Price. $4.26. Price as of December 1, 2023, 4:00 p.m. ET. You’re reading a free …Adaptive’s net loss came in at $50.3 million, compared to $45.3 million in the same period last year. The company’s stock dipped nearly 5% today. Adaptive Biotechnologies hired Goldman Sachs ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual ... Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT …Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third ...Adaptive Biotechnologies Corp. ( NASDAQ: ADPT) stock is down over 72% in the previous 52-weeks and 58.5% YTD. Since its inception, the company has been a loss-maker. Still, the revenues have been ...The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies.The growth-stock investor added to her stakes in UiPath (PATH 26.72%), Prime Medicine (PRME 11.02%), and Adaptive Biotechnologies (ADPT 7.31%) on Thursday. What does Wood see in these three ...If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing …SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth …Mar 31, 2023 · Revenue was $37.6 million for the quarter ended March 31, 2023, representing a 3% decrease from the first quarter in the prior year. Immune Medicine revenue was $16.2 million for the quarter, representing a 22% decrease from the first quarter in the prior year mainly driven by a decline in amortization of the Genentech upfront payment. On average, Wall Street analysts predict. that Adaptive Biotechnologies's share price could reach $8.00 by Nov 13, 2024. The average Adaptive Biotechnologies stock price prediction forecasts a potential upside of 83.07% from the current ADPT share price of $4.37. Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was ... Adaptive Biotechnologies reiterates full year 2022 revenue to be in the range of $185 million to $195 million. Webcast and Conference Call Information. Adaptive Biotechnologies will host a conference call to discuss its first quarter 2022 financial results after market close on Wednesday, May 4, 2022 at 4:30 PM Eastern Time.Traditional biotechnology is the use of natural organisms by humans to create or modify foods or other useful products. Examples of traditional biotechnology include using yeasts for fermentation and practicing selective seed collection to ...Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing.Adaptive Biotechnologies Corporation announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease using clonoSEQ assay technology across the company's... 9db0a67e808.iuF5UsgyO_ajPyA0evrp3ms_tEK0Phtld4MZtKLQRYA.s5AxE5BLZIyTRkdbAM_RlAUMgiTSCiwVG9Z-g9qmC-LO2DMmgwtVt-VZbQAdaptive Biotechnologies. Wood has bought almost 10 million shares of this stock for her ARK Genomic Revolution fund. Adaptive Biotechnologies Corp. ( NASDAQ: ADPT ) is a commercial-stage company ...The latest closing stock price for Adaptive Biotechnologies as of November 24, 2023 is 4.37. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on …Adaptive common stock is expected to begin trading on The Nasdaq Global Select Market on June 27, 2019, under the ticker symbol “ADPT.” The offering is expected to close on July 1, 2019, subject to the satisfaction of customary closing conditions. ... About Adaptive BiotechnologiesMar 9, 2023 · Shares of Adaptive Biotechnologies (ADPT) have gained 1.3% over the past four weeks to close the last trading session at $8.89, but there could still be a solid upside left in the stock if short ... Nov 30, 2023 · The stock price for . Adaptive Biotechnologies (NASDAQ: ADPT) is $4.4 last updated Today at November 30, 2023 at 9:44 PM UTC. Q Does Adaptive Biotechnologies (ADPT) pay a dividend? Adaptive Biotechnologies Corp. company facts, information and financial ratios from MarketWatch. ... 6:33a Bilibili started at buy with $18 stock price target at MizuhoEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.35) to ($1.10) per share. Adaptive Biotechnologies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 13th, 2024 based off prior year's report dates. Read More.Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.Transcript : Adaptive Biotechnologies Corporation, Q4 2022 Earnings Call, Feb 14, 2023 February 14, 2023 at 04:30 pmAdaptive Biotechnologies Stock Performance. NASDAQ:ADPT opened at $4.33 on Tuesday. The firm’s fifty day moving average is $4.59 and its two-hundred day moving average is $6.13. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The firm has a market cap of $626.85 million, a price-to …Aug 23, 2023 · Adaptive Biotechnologies. Another stock that saw a Wall Street firm lower its price target after offering up an earnings report this month is Adaptive Biotechnologies. The immune-system genetic ... Adaptive Biotechnologies is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus ...Adaptive Biotechnologies is a company in transition that has lost 90% of its value in the past couple years. Read why I see no investible angle in ADPT stock.Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of October 04, 2023, 4:00 PM, CST, Adaptive Biotechnologies Corp’s stock price was $4.81. Adaptive Biotechnologies Corp is down 7.85% from its previous closing price of $5.22. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $5.12 and $5.30.Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update. SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive …Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose …Of the 191 institutional investors that purchased Adaptive Biotechnologies stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: ARK Investment Management LLC ($6.79M), Sumitomo Mitsui Trust Holdings Inc. ($4.54M), Nikko Asset Management Americas Inc. ($3.11M), …Adaptive Biotechnologies presently has a consensus target price of $9.50, suggesting a potential upside of 102.13%. Immatics has a consensus target price of $17.67, suggesting a potential upside of 96.08%. Given Adaptive Biotechnologies' higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Immatics.Adaptive Biotechnologies Corp is down 7.85% from its previous closing price of $5.22. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $5.12 and $5.30. Currently, there are 144.40 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive …Adaptive’s net loss came in at $50.3 million, compared to $45.3 million in the same period last year. The company’s stock dipped nearly 5% today. Adaptive Biotechnologies hired Goldman Sachs ...Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Adaptive Biotechnologies ( NASDAQ: ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May. The Seattle-based life ...Jun 30, 2022 · SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended ... In summary, Adaptive Biotechnologies Corp (ADPT) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Lik Wee Lee. Employment: Adaptive Biotechnologies. Crystal L. Mackall. Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Pharmaceuticals, Apricity Health, Syncopation …Jun 30, 2023 · Second Quarter 2023 Financial Results. Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase from the second quarter in the prior year. Immune Medicine revenue was $23.0 million for the quarter, representing a 3% increase from the second quarter in the prior year. Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...So consider, for a moment, the misfortune of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) investors who have held the stock for three years as it declined a whopping 82%.Adaptive Biotechnologies (ADPT) Stock Forecast & Price TargetAdaptive Biotechnologies Corp. company facts, information and financial ratios from MarketWatch. ... 6:33a Bilibili started at buy with $18 stock price target at MizuhoTrack Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsWith Adaptive Biotechnologies stock trading at $4.15 per share, the total value of Adaptive Biotechnologies stock (market capitalization) is $600.28M. Adaptive Biotechnologies stock was originally listed at a price of $40.30 in Jun 27, 2019. If you had invested in Adaptive Biotechnologies stock at $40.30, your return over the last 4 years …What percentage of Adaptive Biotechnologies stock is owned by insiders? 5.20% of Adaptive Biotechnologies stock is owned by insiders. Learn more on ADPT's insider holdings.Nov 30, 2023 · The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies. Adaptive’s net loss came in at $50.3 million, compared to $45.3 million in the same period last year. The company’s stock dipped nearly 5% today. Adaptive Biotechnologies hired Goldman Sachs ...About Adaptive Biotechnologies Stock. Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune ... View Adaptive Biotechnologies Corporation ADPT investment & stock information. Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock ...Adaptive Biotech hires Goldman Sachs to explore ‘strategic alternatives’ for key business lines With revenues declining and net losses increasing, Seattle-based Adaptive Biotechnologies on Thursday said it hired Goldman Sachs to help conduct a review of strategic alternatives for its Minimal Residual Disease (MRD) and Immune Medicine …Adaptive biotechnologies stock

Dec 1, 2022 · SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ... . Adaptive biotechnologies stock

adaptive biotechnologies stock

View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.The Adaptive Biotechnologies stock prediction for 2025 is currently $ 3.58, assuming that Adaptive Biotechnologies shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -19.24% increase in the ADPT stock price. Adaptive Biotechnologies (ADPT) Stock Forecast & Price TargetAdaptive Biotechnologies ( NASDAQ: ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May. The Seattle-based life ...Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Adaptive Biotechnologies Corp. Watch NEW Set a price target alert After Hours Last Updated: Nov 24, 2023 4:51 p.m. EST Delayed quote $ 4.2000 -0.17 -3.89% After Hours Volume: 4.47K Advanced... Adaptive Biotechnologies is a biotechnology company that develops products based on the adaptive immune system. The web page provides stock …At present, SG Americas Securities LLC holds a total of 76,854 shares of Adaptive Biotechnologies Co., compared to its previous ownership of 28,962 shares. The acquisition of an additional 47,892 shares during the first quarter highlights the firm’s belief in the long-term prospects and value of Adaptive Biotechnologies’ stock.The estimated net worth of Chad M. Cohen is at least $134,139.07 as of September 7th, 2021. Mr. Cohen owns 30,979 shares of Adaptive Biotechnologies stock worth more than $134,139 as of November 28th. This net worth evaluation does not reflect any other investments that Mr. Cohen may own. Learn More about Chad M. Cohen's net …Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to facilitate the diagnosis and treatment of disease. Its clinical diagnostic ...Jun 2, 2023 · As of June 02, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $7.46. Adaptive Biotechnologies Corp is up 5.82% from its previous closing price of $7.05. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $6.76 and $7.14. Currently, there are 143.51 million shares of Adaptive ... Jim Halley Shares of Adaptive Biotechnologies (NASDAQ:ADPT) were up 15.7 ... Because of this stock market crash, some wonderful stocks are super cheap in 2022.Nov 29, 2023 · Get a real-time Adaptive Biotechnologies Corporation (ADPT) stock price quote with breaking news, financials, statistics, charts and more. ... The 12-month stock ... Adaptive Biotechnologies announced its first quarter earnings Wednesday, ... Adaptive’s stock value at market close Wednesday was $9.25, down from its high in February 2021 of nearly $70.Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million.Adaptive Biotechnologies Stock Performance. NASDAQ ADPT opened at $4.33 on Tuesday. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The company has a 50-day ...Adaptive Biotechnologies Corp (NASDAQ:ADPT) 4.64 Delayed Data As of Nov 29 +0.27 / +6.18% Today’s Change 2.61 Today ||| 52-Week Range 10.79 -39.27% Year-to-Date Quote Profile News Charts...Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, ... Do the numbers hold clues to what lies ahead for the stock? Adaptive Biotechnologies ...Nov 29, 2023 · In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070.00 in company stock. Percentage Held by Insiders. Only 5.20% of the stock of Adaptive Biotechnologies is held by insiders. Percentage Held by Institutions About Adaptive Biotechnologies Stock. Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune ...THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing …0.86%. $864.11M. ADPT | Complete Adaptive Biotechnologies Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Adaptive Biotechnologies Corp have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 6.00 ...The latest Adaptive Biotechnologies Corporation Registered Shs stock prices, stock quotes, news, and ADPT history to help you invest and trade smarter.Adaptive Biotechnologies Chief Scientific Officer Harlan Robins signs the final beam during a “topping off” ceremony at the company’s future headquarters on Thursday, 23, 2020 in Seattle ...Samples were sent overnight at ambient temperature to Adaptive Biotechnologies (Seattle, WA) for processing. Plasma was isolated within 5 days of collection. ctDNA levels were subsequently determined from isolated plasma via next-generation sequence as described. 13 Clinicians did not have these data available at the …Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. 11-02-2023 at 4:07 PM EDT. Adaptive Announces Launch of Epic Integration for clonoSEQ®. 09-13-2023 at 7:31 AM EDT. Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference. 08-30 …Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual ... Adaptive Biotechnologies Corp stock performance at a glance. Check Adaptive Biotechnologies Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. ADPT Stock Performance. USD USD; Previous close: 4.38: 4.38: Day range: 4.21 - 4.774.21 - 4.77Year range:In addition, Adaptive Biotechnologies Corporation has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal ...Adaptive Biotechnologies is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Adaptive Biotechnologies's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Adaptive Biotechnologies or its management.In addition, Adaptive Biotechnologies Corporation has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal ...2022 Financial Guidance. Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of $185 million to $190 million compared to the previous expectation of $185 million to $195 million. We now expect full year 2022 operating expenses to be below $400 million compared to the previous expectation of between $410 million and $415 ...Agricultural biotechnology is the process of genetically engineering the food we eat. Learn about agricultural biotechnology. Advertisement For thousands of years, humans have manipulated nature to grow the best crops and livestock. By matc...The stock price of Adaptive Biotechnologies Corp (NASDAQ: ADPT) has jumped by 5.72 compared to previous close of 4.37. Despite this, the company has seen a gain of 9.48% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-09 that Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2023 Earnings Conference Call November […]Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Apr 11, 2023 · Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of April 11, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.17. Adaptive Biotechnologies Corp is down 4.89% from its previous closing price of $8.59. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.33 and $8.61. Jun 30, 2022 · SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended ... Jul 21, 2023 · Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of July 21, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.08. Adaptive Biotechnologies Corp is up 4.94% from its previous closing price of $7.70. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.60 and $7.79. This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date ...Nov 30, 2023 · The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies. Sep 30, 2022 · 2022 Financial Guidance. Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of $185 million to $190 million compared to the previous expectation of $185 million to $195 million. We now expect full year 2022 operating expenses to be below $400 million compared to the previous expectation of between $410 million and $415 ... Shares of Adaptive Biotechnologies ... The clinical-stage biotech company's stock closed last week at $7.31, then rose to as high as $9.08 on Wednesday. The stock is up a little more than 10% so ...Hardly a day in March has gone by without Wood making purchases of Adaptive Biotechnologies (ADPT 7.31%), Burning Rock Biotech (BNR-0.12%), or both. ... Get stock recommendations, portfolio ...Ms. Rubinstein ADPT stock SEC Form 4 insiders trading. Julie has made over 40 trades of the Adaptive Biotechnologies stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 22,668 units of ADPT stock worth $194,265 on 6 March 2023.. The largest trade she's ever made was exercising 160,000 units of …... shares and is commonly used to measure how much a company is worth. Market cap history of Adaptive Biotechnologies from 2019 to 2023. 2020 2021 2022 2023 $2B ...Adaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive …You can buy or sell ADPT and other ETFs, options, and stocks. Sign up. About ADPT. Adaptive Biotechnologies Corp. engages in the development of an immune ...Dec 1, 2023 · Adaptive Biotechnologies - ADPT - Stock Price Today - Zacks Adaptive Biotechnologies (ADPT) (Delayed Data from NSDQ) $4.37 USD +0.12 (2.82%) Updated Nov 24, 2023 12:59 PM ET After-Market:... 52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. RSS Feeds.Bluebird Bio. Market Cap. $466M. Today's Change. (11.52%) $0.44. Current Price. $4.26. Price as of December 1, 2023, 4:00 p.m. ET. You’re reading a free …SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ...Adaptive Biotechnologies is expected to report sales of $18.8 million, an decrease of 15.09% over the same period last year. With regard to the current fiscal year, analysts forecast a loss per ...Dec 1, 2022 · SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ... Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update. SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive …SEATTLE, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of a proposed underwritten public offering …Track Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAdaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Historical daily share price chart and data for Adaptive Biotechnologies since 2019 adjusted for splits and dividends. The latest closing stock price for Adaptive Biotechnologies as of November 24, 2023 is 4.37.. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on January 22, 2021.; The Adaptive …If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA. Insider Trading. Relationship. Date.Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.51% and 0.31%, ... Do the numbers hold clues to what lies ahead for the stock? Adaptive Biotechnologies ...Adaptive Biotechnologies is expected to report sales of $18.8 million, an decrease of 15.09% over the same period last year. With regard to the current fiscal year, analysts forecast a loss per .... Oracle corp stock